GlassScriptPhysician profile
Brett E Dorfman
NPI 1558370734
$5,799.58
in general payments reported to CMS, 2019-2025
24 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 92% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $216 · 2021: $459 · 2022: $563 · 2023: $795 · 2024: $618 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153 · Travel and Lodging: $650 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.64 |
| Travel and Lodging | $650.18 |
| Education | $243.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,735.85 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,166.96 | 2019-2025 | Dupixent |
| Genzyme Corporation | $654.98 | 2019-2025 | |
| Medtronic, INC. | $450.04 | 2021-2025 | Propel, Novapak, Pteye Parathyroid Detection System |
| Glaxosmithkline, LLC. | $402.39 | 2022-2025 | Nucala |
| Optinose US, INC. | $263.81 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $193.38 | 2025 | Neffy |
| Medtronic USA, INC. | $150.66 | 2019-2020 | |
| Alk-Abello, INC | $99.02 | 2019-2022 | |
| Checkpoint Surgical, INC | $90.23 | 2021 | |
| Hikma Pharmaceuticals USA | $74.42 | 2023-2025 | Ryaltris |
| Acclarent, INC | $73.30 | 2021-2023 | Acclarent Aera |
| Intersect Ent, INC. | $70.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| 3-D Matrix, INC. | $51.79 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $50.62 | 2019-2023 | Auvi-Q |
| Merz North America, INC. | $39.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.20 | 2021 | |
| Amgen INC. | $34.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.19 | 2024 | Voquezna |
| Integra Lifesciences Corporation | $22.27 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Paratek Pharmaceuticals, INC. | $19.33 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $17.10 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Dorfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.